Rituximab and low-dose cyclosporine combination therapy for steroid-resistant focal segmental glomerulosclerosis
Rituximab and low-dose cyclosporine combination therapy for steroid-resistant focal segmental glomerulosclerosis
复制标题
DOI：
10.1111/ped.12804
复制
发表时间：
2016-03-01
影响因子：
1.4
通讯作者：
Hosoya, Mitsuaki
中科院分区：
文献类型：
--
作者：
Suyama, Kazuhide;Kawasaki, Yukihiko;Hosoya, Mitsuaki
背景我们调查了利妥昔单抗和小剂量环孢素A联合治疗儿童局灶节段性肾小球硬化症（FSGS）的疗效，在儿童激素抵抗型肾病综合征（SRNS. MethodsFSGS儿童SRNS）进行了两次利妥昔单抗和小剂量环孢素A（CyA）联合治疗（RTX-CyAT）。观察RTX-CyAT治疗前后患者的临床表现及实验室检查，并对治疗结果进行评价。CD 19阳性细胞数量减少至
BackgroundWe investigated the efficacy of rituximab and low-dose cyclosporine combination therapy for focal segmental glomerulosclerosis (FSGS) in children with steroid-resistant nephrotic syndrome (SRNS).MethodsFive FSGS children with SRNS were treated twice with rituximab and low-dose cyclosporine (CyA) combination therapy (RTX-CyAT). The clinical features and laboratory data were investigated before and after RTX-CyAT, and the outcomes were assessed.ResultsPrednisolone (PSL) was discontinued 3months after RTX-CyAT in all patients. The number of CD19-positive cells decreased to